152 related articles for article (PubMed ID: 25948588)
21. Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.
Li J; Hu XF; Loveland BE; Xing PX
Exp Hematol; 2009 Nov; 37(11):1284-94. PubMed ID: 19703513
[TBL] [Abstract][Full Text] [Related]
22. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol suppresses gastric cancer cell proliferation and survival through inhibition of PIM-1 kinase activity.
Kim S; Kim W; Kim DH; Jang JH; Kim SJ; Park SA; Hahn H; Han BW; Na HK; Chun KS; Choi BY; Surh YJ
Arch Biochem Biophys; 2020 Aug; 689():108413. PubMed ID: 32473133
[TBL] [Abstract][Full Text] [Related]
24. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
25. Discovery and identification of PIM-1 kinase inhibitors through a hybrid screening approach.
Shao M; Yuan Y; Yu K; Lei K; Zhu G; Chen L; Xiang M
Mol Divers; 2014 May; 18(2):335-44. PubMed ID: 24519385
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of pyrazolo[4,3-a]phenanthridines, a new scaffold for Pim kinase inhibition.
Suchaud V; Gavara L; Giraud F; Nauton L; Théry V; Anizon F; Moreau P
Bioorg Med Chem; 2014 Sep; 22(17):4704-10. PubMed ID: 25087047
[TBL] [Abstract][Full Text] [Related]
28. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
Pierre F; Regan CF; Chevrel MC; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Rice WG; Ryckman DM
Bioorg Med Chem Lett; 2012 May; 22(9):3327-31. PubMed ID: 22460033
[TBL] [Abstract][Full Text] [Related]
29. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
30. The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition.
Stanwell C; Burke TR; Yuspa SH
Cancer Res; 1995 Nov; 55(21):4950-6. PubMed ID: 7585535
[TBL] [Abstract][Full Text] [Related]
31. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
[TBL] [Abstract][Full Text] [Related]
32. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
33. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
34. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
Li K; Li Y; Zhou D; Fan Y; Guo H; Ma T; Wen J; Liu D; Zhao L
Bioorg Med Chem; 2016 Apr; 24(8):1889-97. PubMed ID: 26979485
[TBL] [Abstract][Full Text] [Related]
36. A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide.
Tsuganezawa K; Watanabe H; Parker L; Yuki H; Taruya S; Nakagawa Y; Kamei D; Mori M; Ogawa N; Tomabechi Y; Handa N; Honma T; Yokoyama S; Kojima H; Okabe T; Nagano T; Tanaka A
J Mol Biol; 2012 Mar; 417(3):240-52. PubMed ID: 22306408
[TBL] [Abstract][Full Text] [Related]
37. The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease.
Jackson LJ; Pheneger JA; Pheneger TJ; Davis G; Wright AD; Robinson JE; Allen S; Munson MC; Carter LL
Cell Immunol; 2012; 272(2):200-13. PubMed ID: 22078270
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of new thieno[2,3-b]pyridine derivatives as pim-1 inhibitors.
Naguib BH; El-Nassan HB
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1718-25. PubMed ID: 27541740
[TBL] [Abstract][Full Text] [Related]
39. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
[TBL] [Abstract][Full Text] [Related]
40. Pim kinases in hematological malignancies: where are we now and where are we going?
Mondello P; Cuzzocrea S; Mian M
J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]